Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Family Office-Connected Firm Seek Life Sciences Technologies of All Stages, With Focus on Specialty Medical Devices

15 Feb

A Canada-based firm founded in 2010 consists of a team of entrepreneurs seeking to invest in small-to-mid sized healthcare & pharmaceutical companies. The firm is open to investing in private companies at all stages from seed through growth and expansion. The firm can act as a co-investor or lead, and additionally can leverage distribution networks and partnerships across 4 continents. Typical allocations are < €25 M structured as equity, and may come from a combination of the partners' personal funds, a family office whose wealth is managed by the firm, or the firm's own fund. Portfolio companies focus on specialty pharmaceuticals, biotechnology, medical devices, & ancillary health services. The firm will invest in English-speaking markets.

The firm’s specialty area is in generic pharmaceutical manufacturing and distribution, and manufacturing and distribution of specialty medical devices. Urology and urogynecology devices, injectable medications, cardiovascular medications, dental devices, vaccines, oncology therapeutics, diagnostics, and surgical simulators are reflected in portfolio companies. The firm is open to reviewing technology in all stages of development. Devices that fit well in the focus and distribution regions of portfolio companies are of particular interest.

The firm looks for strong & accomplished management teams and above all, values innovation, transparency, integrity, execution, and fun. The firm may or may not seek a board seat depending on the structure of the allocation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Spain Investment Firm Broadly Seeking Life Science Opportunities in USA & Europe, with Focus on Pre-Clinical Therapeutic Assets

15 Feb

A firm with offices in Spain invests in early-stage companies in the life science and technology sectors. The firm makes investments of EUR 2-6 million in seed and early stage financing rounds. The firm makes both equity and venture debt investments. The firm focuses on investment opportunities in Spain but will also consider deals elsewhere in Europe or in North America.

In the life sciences, the firm focuses on therapeutics and also invests in diagnostics, medical devices and healthcare IT. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. In diagnostics, the firm focuses on opportunities with an identified biomarker or a completed retrospective study. In medical devices and healthcare IT, the firm only invests in companies that are very close to commercialization or already generating revenues. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with no more than EUR 6 million in further private investment.
In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Large Canadian VC Firm Invests in USA & Canada Life Sciences Technologies, Open to All Sectors and Stages of Development

15 Feb

One of the largest Canadian-based venture capital firms focused exclusively on the life sciences industry is making seed and venture investments from its third fund of $125M, and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.

The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.

The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: VC Firm Looks for Medtech and Digital Health Companies in USA and Canada, with Focus on Drug Platform & Consumer-Facing Technologies

15 Feb

A venture capital firm with offices in Boston, San Francisco and Toronto, Ontario invests in several verticals including enterprise software, media and technology, health and life sciences, virtual reality, industrial & business services and blockchain solutions. The fund makes initial investments in the range of $250K – $1M in the form of straight equity or convertible notes and typically targets seed and series A rounds. The firm only leads or co-leads rounds that they can capture a meaningful stake in the company and chunk of the round with $1M. The fund looks to be very active in their investments and add value to portfolio companies through ongoing support and advice as well as leveraging a broad business network. The firm is focused on companies based in the U.S. and Canada and looks to do 10-20 deals per year.

In the healthcare space, the firm is primarily interested in the healthcare IT/digital health, medtech and diagnostics space. The fund is not interested in traditional medical devices and diagnostics that require FDA approval, but rather devices and diagnostics with both a hardware and software component which do not require a traditional regulatory pathway. The fund is most interested in point-of-care and consumer facing technologies as well as platform technologies that help bolster and make the drug discovery/research process more efficient and accurate.

The firm is looking for companies with some type of traction, not necessarily revenue but at least an LOI or pilot in place. The fund will work with novice entrepreneurs, but the founder(s) should at least have deep technical expertise in the area they are pursuing. The firm looks for a board seat as well as pro rata and information rights along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Large Bay Area Based VC Seeking Global Opportunities with Focus in Therapeutics and Digital Health in Life Sciences

8 Feb

A venture capital firm with offices in the Bay area invests in a wide variety of industries and is currently making investments from two separate funds that total to $700M: one being a venture fund investing primarily in Series A and B rounds, and a fund investing in growth stage opportunities. The firm is flexible in investment structure, with typical Series A investments of $5M – $10M upfront with capital reserved for subsequent rounds. The firm usually leads investments and seeks a board seat, but may also invest as part of larger syndicates. The firm is active in their portfolio companies and seeks to add value through network, recruiting, and experience in startup strategy and operations. The firm will invest globally.

The firm is open to investing in multiple sectors, but has a strategic focus in life sciences and digital health. The firm has special interest in therapeutics (especially platform technologies), digital health (especially digital therapeutics and chronic care management) genomics, and synthetic biology.

The firm believes passionately that their role is to support and serve great management teams and entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: VC with Strong Ties to Asia Invests in Early-Stage Therapeutics, Molecular Diagnostics, and Digital Health

8 Feb

An early stage investment firm with offices in North America and Asia focuses on facilitating the development and commercialization of high-potential, high-impact life science innovations arising from the U.S., Canada, South Korea, China and other markets that represent a significant source of opportunities for outsized value creation. The firm makes initial seed investments of US$100K – 1M and can bring in strategic capital from Asia to facilitate global development and market entry. The firm expects to make 2-3 new investments in the coming year.

Within life sciences, the firm is mostly interested in therapeutics, molecular diagnostics and digital health. The firm takes an opportunistic approach when it comes to disease areas and targets early stage innovation on the cusp of preclinical proof-of-concept or validation.

The firm is looking for capable teams developing innovative technologies. The firm works actively with entrepreneurs to devise and implement development and commercialization strategies, help assemble management personnel, and secure additional capital. For more mature opportunities, the firm will add value by using its fundraising, monetization, business development and licensing expertise to help secure investments and partnerships that will fund and expedite eventual commercialization.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Bay Area Venture Capital Looks to Invest in Mobility and Data-Driven Technologies in Life Sciences and Healthcare

8 Feb

A Silicon Valley-based venture capital firm founded in 2012 currently has $300M AUM and investing from its third, $100M fund. The firm focuses on early-stage investments from Seed to Series A, and initial size of investment can range from $500K to up to $3M. The firm reserves a significant part of the fund as follow-on investment. With the current fund, the firm seeks to invest in a total of 6-8 companies, with a preference for companies that are within proximity to their office in the Bay area.

The firm is interested in technologies that incorporate mobility and data. In terms of life sciences and healthcare, this includes digital health, AI and big data in discovery, precision medicine, etc. The firm has made several investments in digital health companies – examples include a mobile coaching app that promotes smarter decisions and better outcomes, a digital health platform for chronic disease management, etc.

The firm looks for driven management teams – relevant industry experience is a definite plus, but not an absolute requirement. The firm works closely with portfolio companies, providing companies with the needed resources and expertise to achieve scalability. The firm prefers to act as the lead investor, typically taking a board seat in such cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.